At veriNOS Pharmaceuticals, we focus on the clinical development of a drug that specifically inhibits a defined cascade that is relevant and common in different disease settings. The activation of iNOS with subsequent excessive production of cell damaging radicals and massive excitotoxic glutamate increase is of crucial importance in all of our indications of interest. Our goal of using Ronopterin is to selectively inhibit upregulated iNOS to reduce radicals and excitotoxic glutamate levels. Our management team consists of experienced biopharma executives with complementary backgrounds, including corporate governance, finance, medicine and science.